Medivation, Astellas sales and marketing update

The U.K.’s NICE issued final guidance recommending Xtandi enzalutamide from Astellas to treat hormone-relapsed, metastatic prostate cancer in men who have no or mild symptoms after androgen deprivation therapy has failed and when chemotherapy is not yet clinically indicated -- one of its approved indications. The decision is in line with final draft guidance issued in December (see BioCentury, Dec. 14, 2015). ...